The Dawn of Allosteric BCR-ABL1 Drugs: From a Phenotypic Screening Hit to an Approved Drug | Journal of Medicinal Chemistry
![Gold Nanoparticles for BCR-ABL1 Gene Silencing: Improving Tyrosine Kinase Inhibitor Efficacy in Chronic Myeloid Leukemia: Molecular Therapy - Nucleic Acids Gold Nanoparticles for BCR-ABL1 Gene Silencing: Improving Tyrosine Kinase Inhibitor Efficacy in Chronic Myeloid Leukemia: Molecular Therapy - Nucleic Acids](https://www.cell.com/cms/attachment/76e1ca46-30ec-49c1-b325-a7c53fedc91f/fx1_lrg.jpg)
Gold Nanoparticles for BCR-ABL1 Gene Silencing: Improving Tyrosine Kinase Inhibitor Efficacy in Chronic Myeloid Leukemia: Molecular Therapy - Nucleic Acids
![Frontiers | Assessing Measurable Residual Disease in Chronic Myeloid Leukemia. BCR-ABL1 IS in the Avant-Garde of Molecular Hematology Frontiers | Assessing Measurable Residual Disease in Chronic Myeloid Leukemia. BCR-ABL1 IS in the Avant-Garde of Molecular Hematology](https://www.frontiersin.org/files/Articles/469178/fonc-09-00863-HTML-r1/image_m/fonc-09-00863-g001.jpg)
Frontiers | Assessing Measurable Residual Disease in Chronic Myeloid Leukemia. BCR-ABL1 IS in the Avant-Garde of Molecular Hematology
![The Clinical Significance of BCR-ABL1 Mutations in Patients With Philadelphia Chromosome–Positive Chronic Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Cell Transplantation - Transplantation and Cellular Therapy, Official Publication of the ... The Clinical Significance of BCR-ABL1 Mutations in Patients With Philadelphia Chromosome–Positive Chronic Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Cell Transplantation - Transplantation and Cellular Therapy, Official Publication of the ...](https://www.astctjournal.org/cms/attachment/4b4ceb2f-a5fa-4bb5-b3d6-9565f0ca7e4c/gr1_lrg.jpg)
The Clinical Significance of BCR-ABL1 Mutations in Patients With Philadelphia Chromosome–Positive Chronic Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Cell Transplantation - Transplantation and Cellular Therapy, Official Publication of the ...
![Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease | Leukemia Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease | Leukemia](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41375-022-01668-0/MediaObjects/41375_2022_1668_Fig1_HTML.png)